Építés alatt – nem éles oldal

Ugrás a tartalomra

Frontlight Research

Vizsgálati helyszín

Mercy Medical Center

Baltimore, Maryland 21202, Egyesült ÁllamokMég nincs intézményhez kötve

25futó vizsgálat
10lezárt vizsgálat

Az itteni vizsgálatok

Miről szól a helyszín 35 vizsgálata, a regiszteri adatlapjaik szerint.

Betegségek: Áttétes emlőrák5 vizsgálat
Zsírmáj (MASLD/MASH)5 vizsgálat
Liver cirrhosis4 vizsgálat
Vastagbélrák4 vizsgálat
Colitis ulcerosa3 vizsgálat
Crohn-betegség3 vizsgálat
Hasnyálmirigyrák3 vizsgálat
Máj- és epeúti rák3 vizsgálat
Melanóma3 vizsgálat
Petefészekrák3 vizsgálat
Tripla negatív emlőrák3 vizsgálat
Gyermekkori daganatok2 vizsgálat
és még 15
Fázis: 3. fázis18 vizsgálat
2. fázis6 vizsgálat
4. fázis2 vizsgálat
1. fázis1 vizsgálat
Állapot: Fut, nem toboroz14 vizsgálat
Toboroz10 vizsgálat
Lezárult9 vizsgálat
Meghívásos bevonás1 vizsgálat
Leállították1 vizsgálat
Fő szponzor: Hoffmann-La Roche4 vizsgálat
Gilead Sciences3 vizsgálat
National Cancer Institute (NCI)3 vizsgálat
Alliance for Clinical Trials in Oncology2 vizsgálat
Amgen2 vizsgálat
és még 17

Futó vizsgálatok

Toboroz
REGN7508 Versus Acetylsalicylic Acid (ASA) for Venous Thromboprophylaxis After Total Knee Arthroplasty in Adult Participants
NCT07213778· 3. fázis· Regeneron Pharmaceuticals· Forrás
Contact: Clinical Trials Administrator
Toboroz
Zymfentra (Infliximab-dyyb) REal World Cohort STudy
NCT07237516· University of North Carolina, Chapel Hill· Forrás
Contact: Liyah Courageux
Toboroz
A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease
NCT06819891· 3. fázis· Hoffmann-La Roche· Forrás
Toboroz
A Trial to Evaluate the Safety and Activity of Fruquintinib in Minority Populations With Advanced, Previously Treated Colorectal Cancer
NCT06562543· 4. fázis· Takeda· Forrás
Contact: Panayotis Ledakis (principal investigator)
Meghívásos bevonás
Utility of Random Biopsies in Patients With Inflammatory Bowel Disease
NCT06560021· Abramson Cancer Center at Penn Medicine· Forrás
Toboroz
LIVERAGE™: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Moderate or Advanced Liver Fibrosis
NCT06632444· 3. fázis· Boehringer Ingelheim· Forrás
Contact: Boehringer Ingelheim
Toboroz
Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
NCT05879926· 3. fázis· NRG Oncology· Forrás
Contact: David A. Riseberg (principal investigator)
Fut, nem toboroz
A Study Evaluating Atezolizumab and Bevacizumab, With or Without Tiragolumab, in Participants With Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma (HCC) (IMbrave152)
NCT05904886· 3. fázis· Hoffmann-La Roche· Forrás
Toboroz
Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis
NCT06051617· 3. fázis· Gilead Sciences· Forrás
Fut, nem toboroz
A Precision Medicine Approach Using Gene Silencing to Treat a Chronic Liver Disease Called Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Adult Participants at Increased Genetic Risk for This Condition
NCT05519475· 2. fázis· Regeneron Pharmaceuticals· Forrás
Fut, nem toboroz
A Phase 3 Study to Evaluate the Effect of Resmetirom on Clinical Outcomes in Patients With Well-compensated NASH Cirrhosis (MAESTRO-NASH-OUTCOMES)
NCT05500222· 3. fázis· Madrigal Pharmaceuticals, Inc.· Forrás
Toboroz
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
NCT05334069· Alliance for Clinical Trials in Oncology· Forrás
Contact: David A. Riseberg (principal investigator)
Fut, nem toboroz
A Study Evaluating the Efficacy and Safety of Giredestrant Plus Everolimus Compared With the Physician's Choice of Endocrine Therapy Plus Everolimus in Participants With Estrogen Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer (evERA Breast Cancer)
NCT05306340· 3. fázis· Genentech, Inc.· Forrás
Toboroz
Testing the Use of Chemotherapy After Surgery for High-Risk Pancreatic Neuroendocrine Tumors
NCT05040360· 2. fázis· SWOG Cancer Research Network· Forrás
Contact: Sandy D. Kotiah (principal investigator)
Fut, nem toboroz
A Study of Tucatinib or Placebo With Trastuzumab and Pertuzumab for Metastatic HER2+ Breast Cancer
NCT05132582· 3. fázis· Seagen, a wholly owned subsidiary of Pfizer· Forrás
Fut, nem toboroz
A Study Evaluating the Efficacy and Safety of Giredestrant Combined With Palbociclib Compared With Letrozole Combined With Palbociclib in Participants With Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer (persevERA Breast Cancer)
NCT04546009· 3. fázis· Hoffmann-La Roche· Forrás
Toboroz
Comparison Between 2-dose Versus 3-dose Regimens of Heplisav B in Cirrhosis
NCT04588077· 4. fázis· Mercy Medical Center· Forrás
Contact: CHAU TO, MD
Fut, nem toboroz
NCI COVID-19 in Cancer Patients, NCCAPS Study
NCT04387656· National Cancer Institute (NCI)· Forrás
Fut, nem toboroz
A Study of Nofazinlimab (CS1003) in Subjects With Advanced Hepatocellular Carcinoma
NCT04194775· 3. fázis· CStone Pharmaceuticals· Forrás
Fut, nem toboroz
Testing MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer
NCT02954874· 3. fázis· National Cancer Institute (NCI)· Forrás
Fut, nem toboroz
Breast Cancer WEight Loss Study (BWEL Study)
NCT02750826· 3. fázis· Alliance for Clinical Trials in Oncology· Forrás
Fut, nem toboroz
Physician/Patient Choice of Either High-Dose Recombinant Interferon Alfa-2B or Ipilimumab, Versus Pembrolizumab in Treating Patients With Stage III-IV High Risk Melanoma That Has Been Removed by Surgery
NCT02506153· 3. fázis· National Cancer Institute (NCI)· Forrás
Fut, nem toboroz
Platinum in Treating Patients With Residual Triple-Negative Breast Cancer Following Neoadjuvant Chemotherapy
NCT02445391· 3. fázis· ECOG-ACRIN Cancer Research Group· Forrás
Fut, nem toboroz
Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel With or Without Carboplatin in Treating Patients With Triple-Negative Breast Cancer
NCT02488967· 3. fázis· NRG Oncology· Forrás
Fut, nem toboroz
HOT: HIPEC in Ovarian Cancer as Initial Treatment
NCT02124421· 2. fázis· Mercy Medical Center· Forrás

Egyszerre toboroz

Hány vizsgálat toboroz itt egyszerre ugyanarra az indikációra. Darabszám, nem értékelés.

Crohn-betegség3 toboroz
Colitis ulcerosa2 toboroz
Hasnyálmirigyrák2 toboroz
Petefészekrák2 toboroz
Vastagbélrák2 toboroz
Akut limfoid leukémia (ALL)1 toboroz
Akut mieloid leukémia (AML)1 toboroz
Áttétes emlőrák1 toboroz
Deep vein thrombosis and pulmonary embolism1 toboroz
Gyomor- és nyelőcsőrák1 toboroz
Hepatitis B (krónikus)1 toboroz
Hólyagrák1 toboroz
Krónikus limfoid leukémia (CLL)1 toboroz
Krónikus mieloid leukémia (CML)1 toboroz
Liver cirrhosis1 toboroz
Melanóma1 toboroz
Mielóma multiplex1 toboroz
Neuroendokrin daganatok1 toboroz
Primer biliáris cholangitis (PBC)1 toboroz
Prosztatarák1 toboroz
Tüdőrák1 toboroz
Vesedaganat1 toboroz
Zsírmáj (MASLD/MASH)1 toboroz

Lezárt vizsgálatok

Lezárult
A Study of JNJ-77242113 in Participants With Moderately to Severely Active Ulcerative Colitis
NCT06049017· 2. fázis· Janssen Research & Development, LLC· Forrás
Lezárult
An Open-Label Study Following Oral Dosing of Seladelpar to Participants With Primary Biliary Cholangitis (PBC) and Hepatic Impairment (HI)
NCT04950764· 1. fázis· Gilead Sciences· Forrás
Lezárult
Study of Semaglutide, and Cilofexor/Firsocostat, Alone and in Combination, in Adults With Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH)
NCT04971785· 2. fázis· Gilead Sciences· Forrás
Lezárult
Prevention of Colorectal Cancer Through Multiomics Blood Testing
NCT04369053· Freenome Holdings Inc.· Forrás
Lezárult
A Study of Atezolizumab Plus Bevacizumab Versus Active Surveillance as Adjuvant Therapy in Patients With Hepatocellular Carcinoma at High Risk of Recurrence After Surgical Resection or Ablation
NCT04102098· 3. fázis· Hoffmann-La Roche· Forrás
Lezárult
Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects With Gastrointestinal, Pancreatic, or Colorectal Cancer
NCT03362177· 3. fázis· Amgen· Forrás
Leállították
An Observational Study of Patients With Chronic Hepatitis B (CHB) Infection
NCT03692897· Target PharmaSolutions, Inc.· Forrás
Lezárult
Study Assessing the Efficacy and Safety of Alpelisib Plus Fulvestrant or Letrozole, Based on Prior Endocrine Therapy, in Patients With PIK3CA Mutant, HR+, HER2- Advanced Breast Cancer Who Have Progressed on or After Prior Treatments
NCT03056755· 2. fázis· Novartis Pharmaceuticals· Forrás
Lezárult
Postmarketing Prospective Study of Melanoma Patients Treated With IMLYGIC® to Characterize Risk of Herpetic Infection
NCT02910557· Amgen· Forrás
Lezárult
A Longitudinal Observational Study of Patients With Nonalcoholic Steatohepatitis (NASH) and Related Conditions Across the Entire Spectrum of Nonalcoholic Fatty Liver Disease (NAFLD)
NCT02815891· Target PharmaSolutions, Inc.· Forrás

Helyszínadatok: ClinicalTrials.govFrissítve: 2026. nov. 15.